Black Diamond Therapeutics, Inc. - Common Stock (BDTX)

These stocks have an unusual volume in today's session

Let's have a look at what is happening on the US markets on Thursday. Below you can find the stocks with an unusual volume in today's session.

These stocks are making the most noise in today's session. Stay tuned for the latest updates!

Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session.

As part of the deal, Servier will develop and commercialize the clinical-stage oncology company’s BDTX-4933, a molecule designed to address solid tumors, including non-small cell lung cancer.

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.

Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an upfront payment of $70 million and up to $710 million in milestone payments.

Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.

Black Diamond Therapeutics reports promising initial Phase 2 data for BDTX-1535 in relapsed EGFR-mutant NSCLC patients. With a 36% objective response rate and encouraging durability, BDTX-1535 shows potential to address osimertinib resistance.

BDTX stock results show that Black Diamond Therapeutic beat analyst estimates for earnings per share the second quarter of 2024.

BDTX stock results show that Black Diamond Therapeutic beat analyst estimates for earnings per share the first quarter of 2024.

The Dow Jones closed lower by around 250 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.